Welcome to Drugdu.com
media

A world first! A serum-free rabies vaccine is about to be launched, marking a major breakthrough in safety.

February 9, 2026  Source: drugdu 26

/> On February 6, 2026, China's vaccine industry achieved a milestone. The serum-free, iterative rabies vaccine, independently developed globally by Amy Vaccine Co., Ltd. (Ningbo) Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of Amy Vaccine Co., Ltd. (06660.HK), successfully passed the on-site registration inspection by the National Medical Products Administration, marking that this world-first vaccine product is only one step away from its official market launch. Rabies is an acute infectious disease with a near 100% fatality rate, and post-exposure vaccination is a crucial preventative measure. However, traditional mainstream rabies vaccines, whether Vero cell rabies vaccines or human diploid cell rabies vaccines, require the use of animal serum during the production process. Residue from animal serum is a significant factor contributing to adverse reactions such as allergies in recipients. The serum-free, upgraded rabies vaccine that passed inspection by Aimei Vaccine is an iterative product designed to address this pain point. This vaccine contains no animal serum, significantly improving safety and reducing the probability of adverse reactions. According to the results of the unblinded Phase III clinical trial, the vaccine demonstrated good safety, immunogenicity, and duration of immunity, fully meeting the pre-set evaluation criteria for clinical trials. Currently, no serum-free rabies vaccines have been approved for marketing globally, and the launch of this product is expected to fill this market gap. China is the world's largest rabies vaccine market. According to Frost & Sullivan, driven by product updates and increased rabies vaccine availability, the market size is projected to reach 14.8 billion yuan by 2030. It is worth noting that after a continuous decline in recent years, the number of rabies cases and deaths in China has rebounded, with 244 cases and 233 deaths reported in 2025, a new high since 2020. This highlights the urgent market demand for safer and more effective vaccines. Policy support also favors the new product. According to the By editor
Share: 
Copyright©2026 Ddu. All rights reserved.
Read more on

Trending Topics

Clinical TrialsCompany InsightDdu CollegeDdu NewsExhibitions & ActivitiesMarket ReportsMarket ViewsNew ApprovalsResearches

Hot Tags

ACTDantibodyAppasthmabreast cancercancerCPhIcredit verificationEMAEUFDAinnovationmedical devicepharmaceuticaltherapyWHO

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more